At least 1 but not more than 5 prior systemic therapies for advanced/recurrent or progressing disease.
Patients with recurrent disease or multiple primaries are ineligible
Patients with recurrent carcinoma of the vulva regardless of previous treatment
Patients must have radiologic evidence of recurrent, refractory or progressive malignant central nervous system (WHO grade III or IV) or solid tumor; for patients with radiologic features of DIPG histologic confirmation of diagnosis is not required though biopsy is suggested if clinically indicated
Patients with measurable recurrent disease of any previous substage (I-IV) are eligible to enrollment
Patients with recurrent disease may have received multiple prior chemotherapies for treatment of their uterine cancer
Patients with esophageal cancer with unresected or recurrent primary tumors in the esophagus are only permitted after discussion of patient with study chair
Participants must have a biopsy-proven diagnosis of primary or recurrent gynecologic cancer for which intracavitary or interstitial brachytherapy is planned as standard treatment; eligible disease sites include primary or recurrent cancer of endometrial, ovarian, cervical, vaginal, or vulvar origin
Recurrent or refractory ALL limited to isolated testicular
Cohort B: Patients with recurrent endometrial cancer may have received up to 2 lines of cytotoxic chemotherapy (adjuvant and one line for recurrent disease, or 2 lines of chemotherapy for recurrent uterine cancer in patients who did not receive adjuvant chemotherapy); patients must have received and failed, or have been intolerant to platinum agents, taxanes, liposomal doxorubicin or other agents known to confer clinical benefit; patients are not required to fail all these agents if, in the investigator’s opinion, patients would benefit from treatment on current protocol
Recurrent or previously resected tumors
Any episode of recurrent disease following completion of aggressive multi-drug frontline therapy.
Recurrent disease that presents >100 days after, or minimal residual disease (MRD) that presents > 30 days after either:
recurrent/refractory disease after they received at least one prior standard treatment regimen
Have minimally symptomatic metastatic castration recurrent prostate cancer with bone lesions; this patient population is defined as having failed hormone treatment and has insurance approval for PROVENGE therapy
PART II: Greater than or equal to 1 week since receipt of standard or investigational HER2-directed therapy for metastatic or recurrent disease
No previous surgery for melanoma (other than complete macroscopic resection as stated above)(i.e. Not recurrent disease)
Participants with recurrent, progressive, or refractory brain tumors
Naive or recurrent patients with LG, non-invasive UTUC in the pyelocalyceal system.
Radiology evidence of reMB or recurrent grade III and IV glioma; patients will be considered for a biopsy or resection of the recurrent/progressive tumor at the discretion of the treating neurosurgeon and neuro-oncologist
Patients who need definitive radiotherapy for treatment of recurrent MB or recurrent grade III or IV glioma
Patients must have resistant/refractory or recurrent neuroblastoma
Recurrent or persistent histologically proven locoregional OCSCC (recurrent T-stage 2-4) that was initially treated with surgery alone; to allow sufficient tumor tissue for the immunological analyses, patients with T-stage 1 OCSCC will be excluded
Patients must have advance, recurrent or metastatic endometrial cancer
Patients must have recurrent disease, histologically proven or imaging suggestive of recurrent disease as determined by principal investigator (PI); prior implantation of Gliadel wafers is acceptable, if tumor recurrence is confirmed by histologic examination of the recurrent tumor
Recurrent or refractory disease for which no further effective standard treatment is available
Patients who already received chemotherapy for recurrent metastatic IBC are not eligible
Recurrent or progressive malignancy requiring anticancer treatment
Patients must have a confirmed recurrent/progressive brain malignancy that have failed at least one prior treatment regimen
Patients with recurrent endometrial cancer.
Prior progression on or within 8 weeks of the last dose of a platinum agent (i.e. cisplatin or carboplatin) for recurrent or metastatic disease
Recurrent or refractory disease according to NCI criteria
Newly-diagnosed chemo-naive or recurrent after curative-intent surgery\r\n* >= 6 months after completion of adjuvant therapy (including chemotherapy and/or radiotherapy)\r\n* No prior treatment with any targeted agent\r\n* Patients who have started first line mFOLFOX6 therapy (+/-trastuzumab for HER2 amplified tumors) may be considered for trial participation if they have received no more than 4 doses of therapy at the time of consent and screening\r\n** These patients will be required to meet ‘next cycle’ parameters for eligibility before commencing treatment on trial rather than being required to meet parameters as indicated below which is for previously untreated metastatic/recurrent patients
First episode of recurrent disease following completion of aggressive multi-drug frontline therapy.
Patients with macroscopic recurrent disease are allowed; macroscopic disease is defined as clinically detectable or evident on radiographic imaging
Persistent or recurrent elevations in levels of EBVDNA exceeding 500 copies/ml in patients previously treated for EBV lymphoproliferative disease (EBVLPD) with chemotherapy and/or Rituxan who do not yet have clinically or radiologically evaluable disease but are at high risk of disease recurrence
Patients must have progression of disease after radiotherapy (including patients that undergo surgery for recurrent disease and are rendered no evidence of disease [NED]); this includes recurrent glioblastoma multiforme (GBM) after receiving all standard first-line treatment, including surgery (if feasible due to neurosurgical and neuro-anatomical considerations) and adjuvant radiotherapy +/- chemotherapy
Subjects with recurrent disease
Subject has gastric outlet syndrome or persistent/recurrent vomiting.
Recurrent disease with an:
In Stage 1, recurrent or metastatic PR-expressing cancer that has the potential to benefit from an anti-progestin treatment including but not limited to endometrial cancer, ovarian, or breast cancer or uterine sarcoma. In Stage 2, recurrent or metastatic PR-expression uterine endometrioid adenocarcinoma that is determined to be APRpos.
Patients must have refractory, recurrent or metastatic disease, which is deemed to be inoperable
Histological diagnosis of recurrent or metastatic cervical, vaginal, or vulvar cancer
Primary or recurrent retroperitoneal or abdominal tumor
For expansion cohort: metastatic platinum-refractory cervical cancer, or metastatic/recurrent platinum-refractory HPV-positive head and neck cancer (as determined by polymerase chain reaction (PCR), in situ hybridization (ISH), or p16 immunohistochemistry (IHC); platinum refractory is defined as recurrent disease within 6 months after receiving cisplatin or carboplatin with radiation for their newly diagnosed disease, or after receiving cisplatin or carboplatin for their recurrent/metastatic disease
Progressive or recurrent breast cancer defined as disease progression or recurrence while on a combination of exemestane with everolimus
Recurrent or refractory ALL limited to isolated testicular disease
Patients who are to be given HDR brachytherapy for treatment of solid tumor of the following:\r\n* Gynecologic (primary cervix and recurrent cervix/uterine cancer)\r\n* Prostate (locally advanced/recurrent cancer)
Patients must have received at least one prior standard systemic therapy with documented recurrent or refractory disease
Patients may have received chemotherapy as a component of their primary tumor treatment but not for recurrent or metastatic disease
Patients with measurable recurrent disease of any previous substage (I-IV) are eligible to enrollment
Patients with recurrent disease may not have received more than three prior chemotherapies for treatment of their uterine cancer
Patients must have clinically evident recurrent disease for the purpose of this study
Patients whom have already undergone secondary cytoreduction for recurrent disease are excluded
Widespread (metastatic) disease, or returned after previous treatment (recurrent)
Previous treatment for metastatic or recurrent disease
Subjects must have recurrent/metastatic disease and may have been previously treated in the recurrent/metastatic setting.
Patients with recurrent uterine LMS
Confirmed recurrent or metastatic disease
Previous chemotherapy for recurrent or metastatic disease.
Patients with recurrent WHO grade III gliomas should have received one prior treatment for recurrent high grade disease
Has received reradiation to recurrent disease (other than standard frontline adjuvant radiation therapy)
Patients must have confirmed Cushing's disease that is persistent or recurrent.
SCCHN that has progressed during or following at least 1 and up to 5 prior systemic treatments for metastatic or recurrent disease deemed to be incurable. Patient who refuse radical resection for recurrent disease or are intolerant of or refused standard first line therapy are eligible to enroll
Patients must have advanced or recurrent disease that is refractory to curative treatment based on imaging or clinical exam.
Patients must have had no more than two prior chemotherapeutic regimens for recurrent endometrial carcinoma. Chemotherapy administered in conjunction with primary radiation as a radio-sensitizer is not counted as a prior treatment for recurrent or advanced disease.
Patients must have had one prior systemic chemotherapeutic regimen for management of recurrent, persistent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab), at least one which must have contained bevacizumab\r\n* NOTE: Patients are allowed to receive 1-2 prior regimens for management of recurrent, persistent or metastatic carcinoma of the cervix; patients who have received more than two prior systemic regimens for management of recurrent, persistent or metastatic carcinoma of the cervix are NOT eligible\r\n* NOTE: Prior adjuvant therapy is NOT counted as a systemic chemotherapeutic regimen for management of recurrent, persistent or metastatic carcinoma of the cervix; adjuvant therapy includes cisplatin given concurrent with primary radiation therapy (CCRT) and adjuvant chemotherapy given following the completion of concurrent chemotherapy and radiation therapy (e.g., paclitaxel and carboplatin for up to 4 cycles)
Patient must have recurrent epithelial ovarian cancer and may have received unlimited prior chemotherapeutic regimens for management of recurrent cancer
Metastatic or recurrent CRC
Histologically confirmed recurrent or metastatic SCCHN; tumor progression or recurrence during or after treatment with only 1 systemic palliative regimen for recurrent or metastatic disease that must have contained a platinum agent; Patients who have only received chemo-radiation with curative intent for treatment of their locally advanced disease or recurrent disease are not eligible. Patients who received concurrent chemo-radiation as part of treatment of their recurrent disease are also not eligible.
Received more than 1 regimen for recurrent or metastatic disease
The trial is open only to women with recurrent, progressive clear cell carcinoma of the ovary
Previously treated with 3 or more systemic regimens given for recurrent and/or metastatic disease
Presence of metastatic or recurrent disease
Tumor progression or recurrence during or after treatment with only 1 systemic palliative regimen for recurrent or metastatic disease that must have contained a platinum agent.
Received more than 1 systematic palliative regimen for recurrent or metastatic disease
Recurrent or persistent (after the failure of chemotherapy) disease that cannot be treated with surgery or radiotherapy;
Locoregionally recurrent or metastatic disease that has not previously been treated with systemic therapy of recurrent or metastatic disease
Patients must have had no more than two prior chemotherapeutic regimens for recurrent management of endometrial carcinoma; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer is not counted as a prior treatment for recurrent or advanced disease
Diagnosis of recurrent or progressive HGG or DIPG
Patients must have recurrent or metastatic tumor located within a previously irradiated field
Interval of at least 12 weeks from prior radiotherapy unless there is either: a) histopathologic confirmation of recurrent tumor, or b) new enhancement on MRI outside of the radiation treatment (RT) field
Receiving any treatment for persistent, progressive or recurrent malignancy.
Progressive or recurrent malignancy defined other than by quantitative molecular assays.
Patients with recurrent or refractory ESFT. Patients with de novo poor prognosis/high risk ESFT: (Eligible for vaccine manufacturing at diagnosis but ONLY ELIGIBLE FOR IMMUNOTHERAPY IF DEMONSTRATES PERSISTENT/RECURRENT/ REFRACTORY DISEASE)
Patients who have undergone recent resection of recurrent or progressive tumor will be eligible as long as they have recovered from the effects of surgery. Evaluable or measurable disease following resection of recurrent tumor is not mandated for eligibility into the study. To best assess the extent of residual measurable disease post-operatively, a MRI should be done no later than 96 hours in the immediate post-operative period or 4-6 weeks post-operatively.
Patients must have received at least one platinum-based chemotherapy for recurrent/advanced disease; recurrent disease is defined as having recurred after definitive therapy and advanced disease is defined as T4 and/or N2 and/or M1; in addition, for completion of Cohort #2, patients must also have received a tubulin inhibitor as part of their therapy for urothelial cancer; for purposes of this evaluation, treatment with chemotherapy regimens where carboplatin or similar is substituted for cisplatin or where a taxane is added or removed will be considered the same regimen; tubulin inhibitors in common use include paclitaxel, docetaxel, and vinblastine; the exception to this requirement applies to women
Histologically documented cutaneous or mucosal malignant melanoma, which is recurrent or metastatic and is not curable by surgical or other means.
History of histological confirmation for recurrent disease, or if recurrent disease is not readily accessible to biopsy, must have two consecutive carcinoembryonic antigen (CEA) or cancer antigen (CA) 19-9 increases, or positron emission tomography (PET) avidity
Recurrent disease with an:
interval of at least 3 weeks between end of surgery for recurrent disease and start of protocol therapy for patients who have undergone surgery for recurrent disease
Any co-morbid condition that poses a greater threat to the patient’s life expectancy than the recurrent myeloma
Recurrent disease or second primary lung cancer (only de novo IIIA disease allowed)
Subjects with recurrent disease
Persistent and/or recurrent cervical cancer o No CNS/spinal metastases
For patients who have undergone resection of recurrent or progressive tumor prior to study enrollment, the following conditions must apply:
Residual disease following resection of recurrent tumor is not mandated for eligibility into the study. To best assess the extent of residual disease post-operatively, an MRI should be performed:
At least 12 weeks from prior radiotherapy to the start of SL-701 unless there is new enhancement outside of the radiation field or unequivocal histopathologic evidence of recurrent tumor.
Any therapeutic regimen for treatment of recurrent tumor after first line treatment with surgery, radiation and temozolomide.
Any number of prior chemotherapy regimens for recurrent disease (Phase I); =< 1 chemotherapy or other non-antiangiogenic regimen for recurrent disease (Phase II)
For recurrent/progressive or refractory disease, a biopsy is not required regardless of number of MIBG avid lesions
Recurrent or refractory BRAFV600 mutant LGG or LCH tumors
Recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease. Note: Subjects with metastatic (and surgically unresectable) melanoma can be enrolled for first-line treatment; Melanoma subjects with CNS involvement may be enrolled.
Patients must have recurrent and/or metastatic disease that is progressive and not amenable to surgery or curative radiotherapy occurring within 6 months of study entry, as evidenced by: at least a 20% increase in radiographically or clinically measurable disease, appearance of any new lesions, or deterioration in clinical status
History of NSCLC treated with surgery and/or radiotherapy previously and disease has been cured or clinically no disease progression for more than 6 months, now isolated recurrent disease in lung parenchyma and without involvement of main bronchus, chest wall, hilar/mediastinal lymph nodes and critical mediastinal structures; biopsy of recurrent disease is recommended
Prior treatment with an EGFR inhibitor as part of a regimen for recurrent or metastatic SCCHN
Subjects who have received more than one course of chemotherapy for recurrent disease
Patients with recurrent T1 disease who do not wish to have cystectomy.
Patient had histological confirmed diagnosis of osteosarcoma of the recurrent sample.
Diagnosis: \r\n* Part A: Recurrent or refractory neuroblastoma or melanoma\r\n* Part B: Recurrent or refractory neuroblastoma or melanoma\r\n* Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma
DCIS prior to index lesion or history of progressive/recurrent DCIS after treatment
Women with of primary or recurrent diagnosis of ovarian, uterine, peritoneal, cervical or vulvar cancer with any of the following:\r\n* < 30 % projected 5 year survival based on histopathological stage\r\n* Non-pelvic recurrent malignancy\r\n* Persistent or progressive disease despite primary treatment with surgery, chemotherapy or\r\n* Palliative performance scale < 60
Recurrent or persistent progressive disease which is refractory to curative therapy or established treatments and cannot be treated with surgery or radiotherapy;
Recurrent cancer following prior resection
First or recurrent presentations
Recurrent or progressive malignancy requiring anti-cancer therapy
Patient has recurrent hyperparathyroidism
Recurrent or progressive malignancy requiring anticancer treatment
History of recurrent or second primary H&N, central nervous system, or thoracic cancer at time of modified barium swallow (MBS) study
Recurrent cancer
Recurrent disease
Recurrent cancer
Patients receiving chemotherapy for a recurrent gynecologic cancer at the University of Wisconsin-Madison Carbone Cancer Center (UWCCC)
Patients with evidence of recurrent malignancy
Subjects must have experienced recurrent/progressive disease following treatment with a non-steroidal aromatase inhibitor (letrozole or anastrozole) in an adjuvant or metastatic setting
Synovial sarcoma that has been treated with standard chemotherapy containing ifosfamide and/or doxorubicin and remains: unresectable or metastatic or progressive/persistent or recurrent disease
A radiological diagnosis of recurrent/relapsed or progressive disease according to RANO criteria.
Recurrent tumors: patients with recurrent grade IV gliomas who have failed cranial radiation therapy
Patients with recurrent disease or a new primary will be allowed
Expected to undergo tumor tissue biopsy for known or suspected prostate cancer (in the primary, recurrent or metastatic disease setting)
Recurrent infratentorial tumor
Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as :
Patients must have recurrent disease for which there is a clinical indication for resection
Any patient with recurrent or progressive cancer
Phase 3: Previous treatment with 3 or more systemic regimens given for recurrent and/or metastatic disease